K-Stemcell’s Arthritis Cell Therapy Set For Phase III In Korea
This article was originally published in PharmAsia News
Executive Summary
In another positive sign for South Korea’s stem cell space, one of the government’s priorities in the biotech sector, K-Stemcell will begin late-stage clinical trials with JOINTSTEM, an autologus adipose-derived stem cell therapy for degenerative arthritis, with a goal of commercialization in 2018.
You may also be interested in...
New OA Cell Therapy On Horizon As JointStem Study Succeeds
A novel stem cell therapy for osteoarthritis developed by South Korean biotech Nature Cell is set to debut in the country this year, providing an alternative for advanced patients who have limited treatment options.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.